Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / due-diligence-memo-hbt.docx
due-diligence-memo-hbt.docx
Parties
Harkness LLP
Helix Bio Therapeutics Inc
Pinnacle Venture Acquisition Corp
Pinnacle Merger Sub Inc
Meridian Pharmaceuticals Inc
Jurisdiction Helix Bio Therapeutics Inc
Delaware General Corp
Equity Inc
Dates
March 15, 2023
June 12, 2018
February 27, 2023
September 14, 2019
May 30, 2023
March 8, 2021
April 3, 2023
January 1, 2020
December 31, 2029
June 5, 2023
Amounts
$40,000,000
$2,100,000
$62.00
$1,140,800
$18,400,000
$485,000
Obligations
While no consent is required, the contractual notice obligation must be fulfilled in a timely manner
Based on our review of the Company's operations, which are limited to a single office and laboratory facility in Cambridge, Massachusetts, and the Company's clinical trial activities (which are conducted through third-party clinical research organizations and hospital-based sites), we have not identified any other jurisdiction in which the Company is required to qualify to do business as a foreign corporation
• Diligence Obligations: HBT is required to use commercially reasonable efforts to develop and commercialize at least one licensed product, and the agreement contains specified development milestones and timelines that HBT must meet to maintain the license in good standing
The agreement further provides that any change of control of HBT (whether by merger, consolidation, sale of all or substantially all assets, or otherwise) shall be deemed an assignment for purposes of this restriction